Sign In
Buy HIMS
$27.51
+0 (+0%)
At Close: Jun 03, 2026
Can Sustained Product Demand Drive HIMS Stock Before Q3 Earnings?
02:40pm, Wednesday, 29'th Oct 2025
Hims & Hers benefits from strong platform engagement and hormonal health launches ahead of third-quarter 2025 earnings.
LEVI & KORSINSKY ISSUES CORRECTION: Securities Fraud Class Action Against Hims & Hers Health, Inc.
11:22am, Wednesday, 29'th Oct 2025
NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- A securities fraud class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) is pending. The lawsuit was filed by Glancy Prongay & Murray LLP. Pre
Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts
06:46pm, Tuesday, 28'th Oct 2025
Hims & Hers Health, Inc. (HIMS) reached $47.12 at the closing of the latest trading day, reflecting a -2.3% change compared to its last close.
HIMS vs. LFMD: Which Telehealth Stock Is the Better Investment Now?
02:51pm, Monday, 27'th Oct 2025
Hims & Hers and LifeMD are reshaping virtual care, but which one leads in earnings growth and platform scale? Let's dive in.
Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:06am, Monday, 27'th Oct 2025
Hims & Hers Health (HIMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hims & Hers: Use This Drop Before It's Too Late
02:51am, Saturday, 25'th Oct 2025
Hims & Hers has experienced a hefty sell-off in recent weeks. This sell-off was mainly caused by short-term turbulence, and I expect the company to resolve these issues in the next quarter. HIMS needs
Hims & Hers Short Interest Nears All-Time High, Buy The Dip?
06:36pm, Friday, 24'th Oct 2025
Shares of Hims & Hers Health Inc. NYSE: HIMS have been the hottest thing in the medical sector, and for good reason. The company's fundamentals are highly attractive for investors who prefer to acqui
Telehealth Stock Could Rebound Off Long-Term Trendline
12:14pm, Thursday, 23'rd Oct 2025
Telehealth stock Hims & Hers Health Inc (NYSE:HIMS) just suffered a steep pullback after President Donald Trump's said Novo Nordisk's (NVO) weight-loss and diabetes drugs , Wegovy and Ozempic, should
Hims & Hers: There's Opportunity In This Crash (Upgrade)
01:58am, Thursday, 23'rd Oct 2025
Hims & Hers offers a compelling "Buy" opportunity after a 30% pullback, despite recent growth concerns and insider selling. HIMS maintains strong long-term growth targets, aiming for $6.5 billion in r
Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today
06:45pm, Wednesday, 22'nd Oct 2025
In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $47.46, marking a -3.85% move from the previous day.
Hims & Hers Advances AI-Powered Personalized Digital Healthcare
11:40am, Wednesday, 22'nd Oct 2025
HIMS accelerates AI-powered care with new tech leadership, personalized treatments and a major $870 million investment push.
Envestnet Portfolio Solutions Inc. Makes New $571,000 Investment in Hims & Hers Health, Inc. $HIMS
04:20am, Wednesday, 22'nd Oct 2025
Envestnet Portfolio Solutions Inc. bought a new position in shares of Hims and Hers Health, Inc. (NYSE: HIMS) in the second quarter, according to the company in its most recent 13F filing with the Sec
HIMS Stock Declines Despite Launch of New Specialty in Women's Health
11:11am, Tuesday, 21'st Oct 2025
Hims & Hers debuts a new women's health specialty, targeting menopause care with personalized treatment plans.
Hims & Hers Q3 Preview: Key Metrics I Want To See For Beating 2030 Guidance
09:09am, Tuesday, 21'st Oct 2025
I expect Hims & Hers Health, Inc. to show stabilizing ARPU around $54+ per user in Q3 despite the GLP-1 slowdown, which could signal meaningful upside to the company's conservative 2030 guidance. I'm
Hims & Hers: Q3 Could Provide Volatility, But The Long-Term Vision Remains Bright
08:07pm, Monday, 20'th Oct 2025
Hims & Hers (HIMS) is emerging as a disruptive force in the obesity treatment market, challenging established GLP-1 drug makers. HIMS has aggressively captured market share, often operating in a legal
